Clinical trial results show sustained myopia control efficacy of highly aspherical lenslets (HAL) in children, saving more than one and a quarter dioptre of myopia over four years.
EssilorLuxottica’s Stellest lenses are based on the optical design of HAL lenses. The clinical trial began in 2018 and was conducted at the Eye Hospital of Wenzhou Medical University in China.
The results were released at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO) and presented by Dr Björn Drobe from EssilorLuxottica’s research and development team.
The study concluded that myopia progression and axial eye elongation in children wearing HAL lenses was slower compared to a modelled control single vision lens group,1 again indicating sustained myopia control efficacy of the lenses in the fourth year.
This latest data follows the recent publication of the three-year clinical trial findings in the American Journal of Ophthalmology, which also highlighted evidence of continued myopia control efficacy of the lens in slowing down myopia progression in children over three years. When children switched to HAL lenses in the third year after two years of wearing single vision lenses, myopia progression and axial eye elongation decreased significantly, compared to children wearing single vision lenses.
Reference
1. Shamp, W., et al. Influence of age and race on axial elongation in myopic children. Invest. Ophthalmol. Vis. Sci.2022;63(7):257 – A0111.
